Startup Dossier
Adcytherix
Marseille-based biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) using novel payload classes to overcome resistance and expand the reach of ADC therapies to poorly responsive tumors. Its lead candidate, ADCX-020, targets high unmet need diseases such as cancer.
active
Typestartup
SectorBioTech
LocationMarseille
About
Marseille-based biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) using novel payload classes to overcome resistance and expand the reach of ADC therapies to poorly responsive tumors. Its lead candidate, ADCX-020, targets high unmet need diseases such as cancer.
Structural DNA
Legal Name
Adcytherix
SIREN
987575784
Founders & Team
Funding Lineage
Series A
11 investors
€105.0M
Oct 2025
Seed
Dawn Biopharma (Lead)
€30.0M
Jun 2024